GENPF (Genix Pharmaceuticals) ROA %: -498.36% (As of Jan. 2026)


What is Genix Pharmaceuticals ROA %?

Genix Pharmaceuticals GENPF ROA % is -498.36% as of Jan. 2026. The stock has 3 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Genix Pharmaceuticals ranks worse than 99.1% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Genix Pharmaceuticals's annualized Net Income for the quarter that ended in Jan. 2026 was $-0.15 Mil. Genix Pharmaceuticals's average Total Assets over the quarter that ended in Jan. 2026 was $0.03 Mil. Therefore, Genix Pharmaceuticals's annualized ROA % for the quarter that ended in Jan. 2026 was -498.36%.

The historical rank and industry rank for Genix Pharmaceuticals's ROA % or its related term are showing as below:

GENPF' s ROA % Range Over the Past 10 Years
Min: -690.72   Med: -43.48   Max: 42.81
Current: -663.51

During the past 13 years, Genix Pharmaceuticals's highest ROA % was 42.81%. The lowest was -690.72%. And the median was -43.48%.

GENPF's ROA % is ranked worse than
99.1% of 1003 companies
in the Drug Manufacturers industry
Industry Median: 2.69 vs GENPF: -663.51

Genix Pharmaceuticals  (OTCPK:GENPF) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jan. 2026 )
=Net Income/Total Assets
=-0.152/0.0305
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.152 / 0)*(0 / 0.0305)
=Net Margin %*Asset Turnover
=N/A %*0
=-498.36 %

Note: The Net Income data used here is four times the quarterly (Jan. 2026) net income data. The Revenue data used here is four times the quarterly (Jan. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Genix Pharmaceuticals ROA % Related Terms


Genix Pharmaceuticals ROA % Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals ROA % Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.73 -22.62 -196.09 -54.08 -692.75

Genix Pharmaceuticals Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -822.22 -428.99 -976.00 -942.86 -498.36

GENPF vs ZTS, UTHR: ROA % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genix Pharmaceuticals ROA % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's ROA % falls into.



Genix Pharmaceuticals ROA % Calculation

Genix Pharmaceuticals's annualized ROA % for the fiscal year that ended in Oct. 2025 is calculated as:

ROA %=Net Income (A: Oct. 2025 )/( (Total Assets (A: Oct. 2024 )+Total Assets (A: Oct. 2025 ))/ count )
=-0.239/( (0.033+0.036)/ 2 )
=-0.239/0.0345
=-692.75 %

Genix Pharmaceuticals's annualized ROA % for the quarter that ended in Jan. 2026 is calculated as:

ROA %=Net Income (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=-0.152/( (0.036+0.025)/ 2 )
=-0.152/0.0305
=-498.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -498.36% mean?
Genix Pharmaceuticals (GENPF) has a ROA % of -498.36% as of Jan. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #994 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 99.1%.
Is Genix Pharmaceuticals' ROA % too high?
Genix Pharmaceuticals' current ROA % is -498.36%. Based on the distribution chart, Genix Pharmaceuticals ranks #994 out of 1003 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Genix Pharmaceuticals' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #994 out of 1003 companies for ROA %. This places Genix Pharmaceuticals in the lower half of its industry. The industry median ROA % is 2.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current ROA % is -498.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current ROA % of -498.36%. The current ROA % is -498.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current ROA % is -498.36% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.